Benzinga | Aug 9, 2021 04:05PM EDT

Organogenesis Sees FY21 Revs $456M-$472M Vs $446.28M Est

For the twelve months ended December 31, 2021, the Company now expects:

* Net revenue of between $456 million and $472 million, representing an increase of approximately 35% to 40% year-over-year, as compared to net revenue of $338.3 million for the twelve months ended December 31, 2020. The 2021 net revenue guidance range assumes: Net revenue from Advanced Wound Care products of between $423 million and $436 million, representing an increase of approximately 44% to 48% year-over-year as compared to net revenue of $294.6 million for the twelve months ended December 31, 2020. Net revenue from Surgical & Sports Medicine products of between $33 million and $36 million, representing a decrease of approximately 18% to 24% year-over-year as compared to net revenue of $43.7 million for the twelve months ended December 31, 2020. Net revenue from the sale of PuraPly products of between $179 million and $187 million, representing an increase of approximately 22% to 27% year-over-year, as compared to net revenue of $147.3 million for the twelve months ended December 31, 2020.

* GAAP net income positive for the twelve months ended December 31, 2021. Adjusted EBITDA positive for the twelve months ended December 31, 2021.